Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen

26th May 2026 Uncategorised 0

Data shows survival benefit in BRAFV600E‑mutant metastatic colorectal cancer

More: Pierre Fabre Laboratories secures CHMP backing for first‑line BRAFTOVI regimen
Source: News